T-Cell Receptor Peptide Therapeutic Vaccine Technology

IMULAN BioTherapeutics, LLC has initiated a multi-site placebo controlled trial to evaluate the effects of their T-Cell Receptor (TCR) peptides for canine atopic dermatitis (allergic dermatitis, atopy).  The TCR Peptides are immune modulating biologics which have been shown to modulate T-helper cell function and Th1/Th2 cytokine profiles.  This immune modulating effect is thought to be a key central target for atopic dermatitis, which is well known to be associated with T-helper cell dysfunction and Th1/Th2 cytokine alterations.  Preliminary studies in dogs have shown promising results in advanced, refractory atopic dermatitis.  Current regulated field trials are underway.

Abstract (atopic dermatitis-preliminary research)  
 
For Veterinarians:  Please read the following to determine if your hospital is eligible to participate
Status: Recruiting sites, inquire with:
Population: Dogs over 1yr of age.
Design: Multi site placebo controlled, crossover (all dogs receive treatment)
Treatment: SQ injection on Day 1 and 14
Diagnostics: CBC, chemistry, peripheral cytokines, serum electrophoresis
General Inclusion: Chronic, non-seasonal atopic dermatitis
General Exclusion: Dogs on immunosuppressive therapy
Special Requirements: Board certified dermatologists preferred.  Clinics able to recruit 6 or more cases and evaluate patients using CADESI score form.
Sponsorship: Veterinarians are provided all test articles, documents, and materials to complete the study, including a fee for every patient that completes the study.

Contact Information: Daniel Gingerich DVM, MS
Chief Scientific Officer - IMULAN BioTherapeutics
email: dgingerich@imulan.com
4221 Mitchell Ave
St. Joseph, MO 65407
www.IMULAN.com